↓ Skip to main content

Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma

Overview of attention for article published in Investigational New Drugs, August 2012
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (77th percentile)
  • High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

patent
3 patents

Readers on

mendeley
94 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Phase I/II study of pegylated arginine deiminase (ADI-PEG 20) in patients with advanced melanoma
Published in
Investigational New Drugs, August 2012
DOI 10.1007/s10637-012-9862-2
Pubmed ID
Authors

Patrick A. Ott, Richard D. Carvajal, Neeta Pandit-Taskar, Achim A. Jungbluth, Eric W. Hoffman, Bor-Wen Wu, John S. Bomalaski, Ralph Venhaus, Linda Pan, Lloyd J. Old, Anna C. Pavlick, Jedd D. Wolchok

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 94 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 94 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 15 16%
Student > Master 15 16%
Researcher 14 15%
Student > Bachelor 12 13%
Student > Doctoral Student 8 9%
Other 14 15%
Unknown 16 17%
Readers by discipline Count As %
Medicine and Dentistry 23 24%
Biochemistry, Genetics and Molecular Biology 18 19%
Agricultural and Biological Sciences 10 11%
Pharmacology, Toxicology and Pharmaceutical Science 9 10%
Chemistry 8 9%
Other 6 6%
Unknown 20 21%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 February 2022.
All research outputs
#4,756,893
of 23,025,074 outputs
Outputs from Investigational New Drugs
#165
of 1,174 outputs
Outputs of similar age
#33,262
of 165,697 outputs
Outputs of similar age from Investigational New Drugs
#3
of 15 outputs
Altmetric has tracked 23,025,074 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,174 research outputs from this source. They receive a mean Attention Score of 4.7. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 165,697 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 77% of its contemporaries.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.